Subject(s)
Catheter-Related Infections/microbiology , Corynebacterium Infections/microbiology , Corynebacterium/isolation & purification , Cystitis/microbiology , Struvite/metabolism , Aged, 80 and over , Bacterial Proteins/metabolism , Carcinoma, Transitional Cell/complications , Carcinoma, Transitional Cell/surgery , Carcinoma, Transitional Cell/therapy , Catheter-Related Infections/etiology , Catheter-Related Infections/metabolism , Catheter-Related Infections/pathology , Corynebacterium Infections/etiology , Corynebacterium Infections/metabolism , Corynebacterium Infections/pathology , Crystallization , Cystitis/metabolism , Cystitis/pathology , Disease Susceptibility , Female , Humans , Hydronephrosis/etiology , Male , Postoperative Complications/etiology , Postoperative Complications/microbiology , Prostatectomy , Prostatic Neoplasms/complications , Prostatic Neoplasms/radiotherapy , Prostatic Neoplasms/surgery , Urease/metabolism , Urinary Bladder Neoplasms/complications , Urinary Catheterization/adverse effects , Urinary Retention/complicationsABSTRACT
We report a case of Chromobacterium violaceum infection and we review the literature for all published cases. C. violaceum grew from a peritoneal fluid of a 47-year-old woman operated on for peritonitis following perforative gastroduodenal ulcer. She was just coming back from a 1-month-holyday in French Guyana, where she might have been in contact with this micro-organism. The patient fully recovered after surgical management associated with antibiotic therapy consisting of ofloxacin plus piperacillin-tazobactam. Among the more than a hundred of published cases of human infections with C. violaceum that we retrieved, there was not any other case of peritonitis.
Subject(s)
Anti-Bacterial Agents/therapeutic use , Chromobacterium , Gram-Negative Bacterial Infections/diagnosis , Peptic Ulcer Perforation/complications , Peptic Ulcer Perforation/surgery , Peritonitis/microbiology , Drug Therapy, Combination , Female , Gram-Negative Bacterial Infections/drug therapy , Humans , Middle Aged , Treatment OutcomeABSTRACT
Serotype 012 represented 15% of 244 isolates of Pseudomonas aeruginosa isolated in the hospital over a 2 year-period and most isolates of this serotype were resistant to multiple antibiotics. Combination experiments showed that fosfomycin and amikacin together were active against 92% of 012 isolates. It is recommended that serotyping be used systematically to identify 012 strains rapidly and fosfomycin/amikacin be considered as a presumptive antipseudomonal therapy in 012 infections.
